Tuberculosis control

In August 2019, Pretomanid, drug developed by the non-profit organization, TB Alliance, has received U.S. Federal Drug Administration (FDA) approval for treatment of extensively drug-resistant tuberculosis or treatment-intolerant/non-responsive multidrug-resistant tuberculosis in combination regimen with bedaquiline and linezolid. Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to at ...

Association “Health Mission” participated in the Capacity building and advocacy workshop related to people centered TB care jointly organized by the TB Europe Coalition and European Respiratory Society in Zagreb, Croatia, 16-17 April 2019. The workshop gathered civil society organizations and health care professionals from across the Balkan region. The two-day ...

In the 21st century, tuberculosis (TB) remains one of the world’s largest public health problems. Despite the fact that with timely diagnosis and proper treatment most people can be cured, this disease causes death of 5000 people every day. (more about tuberculosis) Tuberculosis control is defined by the World Health ...